Oral Genome is revolutionizing preventive healthcare with its highly sensitive and specific saliva-based, periodontal caries (tooth decay), and diabetes screening test, delivering results that exceed industry standards. With 89.7% sensitivity and 95% specificity, Oral Genome ensures accurate disease detection, minimal false positives, and industry-leading reliability.
Unlike early Covid-19 tests that faced scrutiny for inconsistent results, Oral Genome’s rigorous laboratory validation and clinical pilot program confirm its precision. The device accurately identifies key biomarkers, including MMP-8 and P. gingivalis, crucial for diagnosing periodontal disease and caries—all in a single, non-invasive test.
Proven Accuracy Beyond Industry Standards
- Sensitivity: 89.7% – Minimizes false negatives for reliable detection.
- Specificity: 95% – Distinguishes disease-free individuals with confidence.
- Clinical Validation – Outperforms standard FDA and EU diagnostic accuracy requirements.
“Our goal is to set a new benchmark in salivary diagnostics, ensuring patients and providers trust the results,” said Dr. Tina Saw, CEO. “Oral Genome eliminates uncertainty, delivering cost-effective point of care salivary testing in preventive healthcare.”
As demand for reliable, non-invasive diagnostics grows, Oral Genome is leading the way. Its cutting-edge technology and affordability position it for widespread adoption, transforming oral and systemic health monitoring.
For more information, visit www.oralgenome.com or contact [email protected].
Junevity, a biotech that focuses on longevity by developing what they describe as “cell reset therapeutics”, has raised $10 million in seed funding. Goldcrest Capital and Godfrey Capital led the funding round. Its technology relies on licensed research by co-founder Dr. Janine Sengstack at the University of California at San Francisco, according to a press release.
Junevity uses large-scale human data and AI to identify genes or transcription factors that can regulate cell damage and develops siRNA therapeutics against these targets to return cells to health. Its initial therapeutics under development will treat Type 2 diabetes, obesity and frailty.
To read more, click here.
Coral, a Canadian virtual care startup supporting women entering perimenopause and menopause, has completed a $2.9 million ($4.1 million CAD) seed funding round. and the launch of its virtual care platform. Brightspark Ventures led the round, with participation from Diagram, The51 Ventures, and angel investors. Coral will use the fresh capital to support integrated, personalized solutions for care navigation for women.
To read more, click here.
Keragon, an AI-powered HIPAA-compliant automation platform for healthcare, has raised $7.5 million in a seed funding round. Upfront Ventures led the round with investors Afore Capital, Focal, and 25m Health adding to their initial investments. To date, Keragon has raised a total of $10.5 million. The no-code workflow automation platform launched out of stealth in June 2024, according to a press release.
To read more, click here.
The MedCity INVEST Pitch Perfect contest is currently accepting applications from startups across digital health, medtech, diagnostics and biopharma. The contest offers the opportunity for healthcare entrepreneurs to pitch to an audience of healthcare investors and stakeholders. The conference will be held at the Willis Tower in Chicago on May 20 and 21. The deadline for applications is February 21.
To review the criteria and submit an application, click here.
Credit: Getty Images, pixelliebe
This is a paid member feature of MedCitizens. Please submit here and join!
